Repligen Corp
NASDAQ:RGEN
Intrinsic Value
Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. [ Read More ]
The intrinsic value of one RGEN stock under the Base Case scenario is 71.97 USD. Compared to the current market price of 157.06 USD, Repligen Corp is Overvalued by 54%.
Valuation Backtest
Repligen Corp
Run backtest to discover the historical profit from buying and selling RGEN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Repligen Corp
Current Assets | 1.1B |
Cash & Short-Term Investments | 751.3m |
Receivables | 124.2m |
Other Current Assets | 235.6m |
Non-Current Assets | 1.7B |
PP&E | 323m |
Intangibles | 1.4B |
Other Non-Current Assets | 2.8m |
Current Liabilities | 158.2m |
Accounts Payable | 19.6m |
Accrued Liabilities | 39.1m |
Other Current Liabilities | 99.5m |
Non-Current Liabilities | 695m |
Long-Term Debt | 510.1m |
Other Non-Current Liabilities | 184.9m |
Earnings Waterfall
Repligen Corp
Revenue
|
638.8m
USD
|
Cost of Revenue
|
-323.5m
USD
|
Gross Profit
|
315.2m
USD
|
Operating Expenses
|
-228.5m
USD
|
Operating Income
|
86.8m
USD
|
Other Expenses
|
-45.2m
USD
|
Net Income
|
41.6m
USD
|
Free Cash Flow Analysis
Repligen Corp
What is Free Cash Flow?
RGEN Profitability Score
Profitability Due Diligence
Repligen Corp's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
Score
Repligen Corp's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
RGEN Solvency Score
Solvency Due Diligence
Repligen Corp's solvency score is 91/100. The higher the solvency score, the more solvent the company is.
Score
Repligen Corp's solvency score is 91/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RGEN Price Targets Summary
Repligen Corp
According to Wall Street analysts, the average 1-year price target for RGEN is 208.71 USD with a low forecast of 161.6 USD and a high forecast of 236.25 USD.
Ownership
RGEN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
RGEN Price
Repligen Corp
Average Annual Return | 43.18% |
Standard Deviation of Annual Returns | 60.36% |
Max Drawdown | -65% |
Market Capitalization | 8.8B USD |
Shares Outstanding | 55 838 500 |
Percentage of Shares Shorted | 10% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The company is headquartered in Waltham, Massachusetts and currently employs 1,852 full-time employees. The firm's bioprocessing business consist of four franchises, filtration; chromatography; process analytics; and proteins. The Filtration products are used in process development and process scale production. The Chromatography franchise includes products used in downstream purification, development, and manufacturing of biological drugs. The Process Analytics products allow end-users to make in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins franchise is represented by its Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all monoclonal antibody (mAb) based drugs on the market.
Contact
IPO
Employees
Officers
The intrinsic value of one RGEN stock under the Base Case scenario is 71.97 USD.
Compared to the current market price of 157.06 USD, Repligen Corp is Overvalued by 54%.